April 7th, 2016, Vancouver, B.C. – Veritas Pharma Inc. (“VRT” or the “Company”) (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP) is pleased to announce that Cannevert Therapeutics Ltd. has delivered its first quarterly scientific progress report.
The report outlines the establishment and standardization of the chemical and pharmacological assays that will be used to screen new cannabis cultivars.  Veritas’ CEO, Dr. Lui Franciosi commented, “We are pleased with what the Cannevert team has achieved thus far within budget.  We think that the chemical and biological assays now in place will allow us to quickly process different cannabis strains over the coming months.”
Dr. Dom Spina, Veritas’ independent Board member, also reviewed the quality of the report especially for its scientific basis.  He felt that “the report was well organized and the methods presented for the assays were sufficient to indicate that the right standard procedures and controls would be used to adequately assess the safety and efficacy of each strain.”
Cannevert’s next quarterly report is expected June 2016.
Also, the Company is pleased to announce that CEO, Dr. Franciosi has joined Cannevert’s Board of Directors.

About VERITAS Pharma Inc.

Veritas Pharma Inc. is an early stage pharmaceutical company developing innovative medicinal cannabis cultivars for specific disease conditions such as chronic pain, emesis (nausea/vomiting), and epilepsy. Using a ‘lean and mean’ approach to product development, the company aims to select candidate cultivars using classical pharmacology techniques and then immediately evaluate them in the clinic to maximize both product value and shareholder return. Veritas’s scientists are an inter-disciplinary team that consists of chemists, pharmacologists, anesthetists, and clinical pharmacologists. Their focus is to use their knowledge to streamline the development of cannabis based treatments to capture considerable market share. Also through its wholly owned subsidiary, Sechelt Organic Marijuana Corp., has applied to Health Canada for a medical marijuana production and distribution license under the Marihuana for Medical Purposes Regulations (the “MMPR“).

On behalf of the Board of Directors Veritas Pharma Inc.
“Dr. Lui Franciosi”
Dr. Lui Franciosi
Chief Executive Officer

Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com.

Investor and Public Relations Contact

Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785
Email: [email protected]
Website: www.veritaspharmainc.com

The CSE has not reviewed, nor approved or disapproved the content of this press release.

The Veritas Newsletter

Enter your email to receive news alerts and updates from Veritas Pharma.

You have Successfully Subscribed!